Designing eligibility and evaluation criteria for antibacterial pull incentives: a comparative review of implemented and emerging initiatives
Michael Anderson, Emily O'Neill, Gunnar Ljungqvist, Avi Cherla, Zilke Claessens, Elise Schoefs, Nick Crabb, Warren Cowell, Jennifer Cohn, Deepali Patel, Elias Mossialos · 2026
Read Designing eligibility and evaluation criteria for antibacterial pull incentives: a comparative review of implemented and emerging initiatives by Michael Anderson, Emily O'Neill, Gunnar Ljungqvist, Avi Cherla, Zilke Claessens, Elise Schoefs, Nick Crabb, Warren Cowell, Jennifer Cohn, Deepali Patel, Elias Mossialos (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13572082.txt.
Description
Germ drugs are hard to sell, so states now pay pull prizes that make new drugs worth the build. Michael Anderson and co-authors ask in a 2026 review which drugs and firms may claim such prizes in each land. They sift past reviews, grey files, and a global hub list to map the rules.
Twenty eight prizes turned up, most live and some in draft. All the live sets aimed at high need germs. Rules on firm duties, such as fair access and green care, ran patchy. The UK and Swedish sets were the most broad, with the UK set in use across all grades. The team urges a shared core of rules with room for each land's needs.
Catalog record
| CREATOR | Michael Anderson, Emily O'Neill, Gunnar Ljungqvist, Avi Cherla, Zilke Claessens, Elise Schoefs, Nick Crabb, Warren Cowell, Jennifer Cohn, Deepali Patel, Elias Mossialos |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |